CGAS and cervical squamous intraepithelial neoplasia: Beyond CIN, other genetic and epigenetic alterations—such as loss-of-function mutations in STING or cGAS, promoter hypermethylation [106], or overexpression of DNA exonucleases like TREX1 [107]—may also diminish the efficacy of STING agonists.